Pivoting from reni-cel's collapse to a one-time CRISPR LDL therapy, with first human data as the make-or-break proof point

Bull

A positive outcome would be at least three HeFH patients demonstrating >80% LDL-C reduction at one month or more of follow-up, mirroring the NHP data and satisfying the warrant milestone threshold — this would validate CRISPR-based in vivo PCSK9 editing as a durable, one-time LDL-lowering approach in humans. Such a result would reframe Editas as a credible cardiovascular gene editing company, materially de-risk the platform, and likely trigger warrant exercises that extend the cash runway well beyond H2 2028.

Bear

The most likely failure modes are insufficient LDL-C reduction in humans relative to the NHP benchmark, off-target editing signals or unexpected hepatotoxicity that raise safety flags, or dose-limiting tolerability issues with the LNP delivery vehicle that prevent reaching therapeutically relevant exposures — any of which would cast doubt on whether the preclinical package was predictive and undermine the entire pivot thesis. A modest reduction (e.g. 40-60% LDL-C lowering) rather than outright failure would be the most damaging scenario, as it would be too weak to differentiate from approved therapies yet too ambiguous to cleanly abandon the program.